- ISIN
- US03969T1097
- CUSIP
- 03969T109
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Apr 16, 2020
Highlights
- Market Cap
- $217.42M
- Enterprise Value
- $25.73M
- EPS (TTM)
- -$1.81
- Total Revenue (TTM)
- $46.80M
- Gross Profit (TTM)
- $40.72M
- EBITDA (TTM)
- -$84.61M
- Year Range
- $5.85 - $24.17
- Target Price
- $22.50
- ROA (TTM)
- -20.28%
- ROE (TTM)
- -26.01%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
ARCT Performance Chart
Arcturus Therapeutics Holdings Inc. (ARCT) is up 24.8% since the beginning of the year. At $8 per share, ARCT is trading 68.3% below its 52-week high of $24. Investors who bought $1,000 worth of ARCT shares 5 years ago would now be looking at an investment worth $249.
Loading charts...
Returns By Period
Arcturus Therapeutics Holdings Inc. (ARCT) has returned 24.80% so far this year and -41.15% over the past 12 months.
Arcturus Therapeutics Holdings Inc.
- 1D
- -1.54%
- 1M
- -10.74%
- YTD
- 24.80%
- 6M
- 16.08%
- 1Y
- -41.15%
- 3Y*
- -34.22%
- 5Y*
- -24.26%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 0.13%
- 1M
- 5.68%
- YTD
- 11.16%
- 6M
- 11.10%
- 1Y
- 27.46%
- 3Y*
- 21.12%
- 5Y*
- 12.66%
- 10Y*
- 13.75%
ARCT Monthly Returns History
Based on dividend-adjusted daily data since Apr 16, 2020, ARCT's average daily return is +0.16%, while the average monthly return is +2.28%. At this rate, an investment would double in approximately 2.6 years.
Historically, 47% of months were positive and 53% were negative. The best month was Apr 2020 with a return of +102.9%, while the worst month was Dec 2020 at -52.7%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 6 months.
On a daily basis, ARCT closed higher 49% of trading days. The best single day was Aug 3, 2021 with a return of +68.1%, while the worst single day was Dec 29, 2020 at -54.2%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 21.86% | 10.17% | -6.20% | 11.66% | -8.12% | -3.41% | 24.80% | ||||||
| 2025 | 0.00% | -1.06% | -36.93% | 20.96% | -2.19% | 3.83% | -6.15% | 39.31% | 8.35% | -45.90% | -31.90% | -9.72% | -63.88% |
| 2024 | 4.57% | 17.56% | -12.87% | -24.28% | 51.78% | -37.26% | -3.66% | -10.06% | 10.00% | -23.61% | 3.44% | -7.47% | -46.18% |
| 2023 | 24.59% | -23.10% | 47.51% | 11.06% | 2.70% | 4.90% | 21.90% | -13.19% | -15.82% | -25.24% | 25.34% | 31.70% | 85.91% |
| 2022 | -29.40% | -8.27% | 12.47% | -28.12% | 2.58% | -20.82% | 11.50% | -20.00% | 5.56% | 19.43% | 4.18% | -8.03% | -54.17% |
| 2021 | 67.04% | -27.31% | -21.59% | -11.23% | -20.29% | 15.81% | -7.48% | 75.06% | -12.83% | -5.92% | -11.57% | -6.89% | -14.68% |
Benchmark Metrics
Arcturus Therapeutics Holdings Inc. has an annualized alpha of 9.58%, beta of 1.75, and R2 of 0.09 versus S&P 500 Index. Calculated based on daily prices since April 17, 2020.
- This stock participated in 200.77% of S&P 500 Index downside but only 99.15% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.09 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 9.58%
- Beta
- 1.75
- R²
- 0.09
- Upside Capture
- 99.15%
- Downside Capture
- 200.77%
Return for Risk
Risk / Return Rank
ARCT ranks 25 for risk / return — below 25% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Arcturus Therapeutics Holdings Inc. (ARCT) and compare them to S&P 500 Index.
| ARCT | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | -0.44 | 2.39 | -2.83 |
Sortino ratioReturn per unit of downside risk | -0.05 | 3.25 | -3.31 |
Omega ratioGain probability vs. loss probability | 0.99 | 1.43 | -0.44 |
Calmar ratioReturn relative to maximum drawdown | -0.54 | 3.11 | -3.66 |
Martin ratioReturn relative to average drawdown | -0.77 | 14.38 | -15.15 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Arcturus Therapeutics Holdings Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Arcturus Therapeutics Holdings Inc. was 95.23%, occurring on Nov 20, 2025. The portfolio has not yet recovered.
The current Arcturus Therapeutics Holdings Inc. drawdown is 93.81%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 bear market2025 | -95.23%Nov 2025 | 4y 11mo | — | 5y 5moDec 2020 - now |
2020 bear market2020 | -49.03%Jun 2020 | 14d | 1mo 13d | 1mo 27dMay 2020 - Jul 2020 |
2020 bear market2020 | -45.38%Nov 2020 | 0s | 18d | 18dNov 2020 - Nov 2020 |
2020 bear market2020 | -40.67%Sep 2020 | 1mo 28d | 1mo 13d | 3mo 11dJul 2020 - Nov 2020 |
2020 correction2020 | -14.41%May 2020 | 2d | 4d | 6dMay 2020 - May 2020 |
Drawdown Indicators
| ARCT | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -95.23% | -56.78% | -38.45% |
Max Drawdown (1Y)Largest decline over 1 year | -74.53% | -9.10% | -65.43% |
Max Drawdown (3Y)Largest decline over 3 years | -86.71% | -18.90% | -67.81% |
Max Drawdown (5Y)Largest decline over 5 years | -89.87% | -25.43% | -64.44% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -93.81% | 0.00% | -93.81% |
Average DrawdownAverage peak-to-trough decline | -72.96% | -10.72% | -62.24% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 52.60% | 1.97% | +50.63% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Arcturus Therapeutics Holdings Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Arcturus Therapeutics Holdings Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for ARCT relative to other companies in the Biotechnology industry. Currently, ARCT has a P/S ratio of 4.5. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for ARCT in comparison with other companies in the Biotechnology industry. Currently, ARCT has a P/B value of 1.1. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with ARCT
Add Arcturus Therapeutics Holdings Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with ARCT